Börse:
34,270€
-0,25%
Echtzeit-Aktienkurs Pacira BioSciences
Bid:
33,920€
Ask:
34,620€
| Allgemeine Informationen | ||
|---|---|---|
| Börsenwert: | 1,41 Mrd. EUR (41,22 Mio. x 34,270€) | |
| Website: | - | |
| Sektor: | Medizin / Biotechnologie | |
| News-Radar | |
|---|---|
| dpa-AFX Pro - | Newsbot - |
| dpa-AFX - | Reuters - |
| 2015 | 2016 | 2017 | 2018 | |
|---|---|---|---|---|
| KUV | 5,07 | 4,65 | 4,86 | 4,19 |
| KGV | 856,75 | - | - | - |
| Div. Rend. | - | - | - | - |
Echtzeit-Chart der Pacira BioSciences Aktie
Börsenkurse Pacira BioSciences
| Börse Stuttgart | 33,825€ | 2500 | 34,750€ | 2500 | 34,288€ | 1,32% |
| Tradegate | 33,920€ | 890 | 34,620€ | 870 | 34,270€ | 0,24% |
| Lang & Schwarz | 33,950€ | 731 | 34,580€ | 731 | 34,265€ | 0,18% |
| Euro Indikation | 33,920€ | 0 | 34,620€ | 0 | 34,270€ | -0,25% |
| Dollar Indikation | 37,575$ | 0 | 38,309$ | 0 | 37,942$ | 0,83% |
Fundamentaldaten der Pacira BioSciences Aktie
Aktuelle Geschäftsentwicklung
Sie benötigen die TraderFox Börsensoftware, um die aktuelle Geschäftsentwicklung einsehen zu können.
Income Statement: 10-Year-Summary
| Datum | Umsatz | EBIT | Gewinn | EPS | Dividende | KGV | KUV |
|---|---|---|---|---|---|---|---|
| 2018 | 337,28 Mio. | -0,43 Mio. | -0,47 Mio. | -0,01 | 0,00% | - | 4,19 |
| 2017 | 286,63 Mio. | -42,47 Mio. | -42,61 Mio. | -1,07 | 0,00% | - | 4,86 |
| 2016 | 276,37 Mio. | -37,84 Mio. | -37,95 Mio. | -1,02 | 0,00% | - | 4,65 |
| 2015 | 249,00 Mio. | 2,12 Mio. | 1,86 Mio. | 0,04 | 0,00% | 856,75 | 5,07 |
| 2014 | 197,67 Mio. | -13,54 Mio. | -13,72 Mio. | -0,39 | 0,00% | - | 6,27 |
| 2013 | 85,55 Mio. | -64,35 Mio. | -63,91 Mio. | -1,93 | 0,00% | - | 13,47 |
| 2012 | 39,08 Mio. | -52,28 Mio. | -52,28 Mio. | -1,72 | 0,00% | - | 28,60 |
| 2011 | 15,69 Mio. | -43,33 Mio. | -43,33 Mio. | -2,64 | 0,00% | - | 55,35 |
| 2010 | 14,56 Mio. | -27,15 Mio. | -27,15 Mio. | -3,58 | 0,00% | - | 17,82 |
| 2009 | 15,01 Mio. | -31,71 Mio. | -31,71 Mio. | -4,19 | 0,00% | - | 17,30 |
Profil der Pacira BioSciences Aktie
Pacira Pharmaceuticals, Inc. is a specialty pharmaceutical company. It develops, commercializes, and manufactures pharmaceutical products for use in hospitals and ambulatory surgery centers. It develops pharmaceutical products based on its proprietary DepoFoam drug delivery technology. The company markets EXPAREL, a liposome injection of bupivacaine, an amide-type local anesthetic, indicated for administration into the surgical site to produce postsurgical analgesia; and DepoCyt(e), a liposomal formulation of the chemotherapeutic agent cytarabine indicated for the intrathecal treatment of lymphomatous meningitis, a cancer of the immune system. Its product pipeline comprise EXPAREL that has completed Phase II clinical trials for postsurgical analgesia-nerve block administration; DepoNSAID, which is in preclinical trials for the relief of that is in preclinical trials acute pain; and DepoTXA is currently in pre-clinical development, which is used to treat or prevent excessive blood loss during surgery by promoting hemostasis. Pacira Pharmaceuticals was founded in December 2006 and is headquartered in Parsippany, NJ.
TraderFox GmbH:
Impressum & Datenschutz -
Allgemeine Geschäftsbedingungen